Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer’s

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

Medicare puts brake on Lilly’s Alzheimer’s test

Will only reimburse new Alzheimer's diagnostic Amyvid for patients in trials

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

- PMLiVE

Baxter’s Gammagard latest disappointment in Alzheimer’s

Fails to show improvement in cognitive and functional measures

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

FDA explains draft Alzheimer’s guidance in NEJM editorial

Intends to relax requirements in patient function and cognition

- PMLiVE

Merck taps Luminex for Alzheimer’s biomarker

Licenses companion diagnostic to use in its clinical trials

- PMLiVE

Pharma CEOs team up to tackle Alzheimer’s

Call for Global Alzheimer’s Action Plan to prevent and treat neurological condition by 2025

- PMLiVE

FDA proffers guidance for new Alzheimer’s drugs

Encourages approach that tackles disease in its early stages

- PMLiVE

Lilly gets go-ahead for Alzheimer’s diagnostic in EU

Amyvid can detect amyloid plaques – a hallmark of the condition

Canadian charity aims to tackle stigma of dementia

Alzheimer Society launches campaign during its Alzheimer’s Awareness Month

Daiichi Sankyo launches Alzheimer’s campaign

Disease awareness drive will include TV commercials, newspaper adverts and a website

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links